



CD5 expression promotes IL-10 production through activation of the MAPK/Erk pathway and upregulation of TRPC1 channels in B lymphocytes

Submitted by Beatrice Guillaumat on Wed, 12/05/2018 - 14:37

Titre	CD5 expression promotes IL-10 production through activation of the MAPK/Erk pathway and upregulation of TRPC1 channels in B lymphocytes
Type de publication	Article de revue
Auteur	Garaud, Soizic [1], Taher, Taher E [2], Debant, Marjolaine [3], Burgos, Miguel [4], Melayah, Sarra [5], Berthou, Christian [6], Parikh, Kaushal [7], Pers, Jacques-Olivier [8], Luque Paz, Damien [9], Chiocchia, Gilles [10], Peppelenbosch, Maikel [11], Isenberg, David A [12], Youinou, Pierre [13], Mignen, Olivier [14], Renaudineau, Yves [15], Mageed, Rizgar A [16]
Editeur	Springer Nature [academic journals on nature.com]
Type	Article scientifique dans une revue à comité de lecture
Année	2018
Langue	Anglais
Date	Février 2018
Pagination	158-170
Volume	15
Titre de la revue	Cellular & molecular immunology
ISSN	2042-0226
Résumé en anglais	CD5 is constitutively expressed on T cells and a subset of mature normal and leukemic B cells in patients with chronic lymphocytic leukemia (CLL). Important functional properties are associated with CD5 expression in B cells, including signal transducer and activator of transcription 3 activation, IL-10 production and the promotion of B-lymphocyte survival and transformation. However, the pathway(s) by which CD5 influences the biology of B cells and its dependence on B-cell receptor (BCR) co-signaling remain unknown. In this study, we show that CD5 expression activates a number of important signaling pathways, including Erk1/2, leading to IL-10 production through a novel pathway independent of BCR engagement. This pathway is dependent on extracellular calcium (Ca) entry facilitated by upregulation of the transient receptor potential channel 1 (TRPC1) protein. We also show that Erk1/2 activation in a subgroup of CLL patients is associated with TRPC1 overexpression. In this subgroup of CLL patients, small inhibitory RNA (siRNA) for CD5 reduces TRPC1 expression. Furthermore, siRNAs for CD5 or for TRPC1 inhibit IL-10 production. These findings provide new insights into the role of CD5 in B-cell biology in health and disease and could pave the way for new treatment strategies for patients with B-CLL.
URL de la notice	http://okina.univ-angers.fr/publications/ua18249 [17]
DOI	10.1038/cmi.2016.42 [18]

Lien vers le document	https://www.nature.com/articles/cmi201642 [19]
Titre abrégé	Cell. Mol. Immunol.
Identifiant (ID) PubMed	27499044 [20]

Liens

- [1] <http://okina.univ-angers.fr/publications?f%5Bauthor%5D=31289>
- [2] <http://okina.univ-angers.fr/publications?f%5Bauthor%5D=31290>
- [3] <http://okina.univ-angers.fr/publications?f%5Bauthor%5D=31291>
- [4] <http://okina.univ-angers.fr/publications?f%5Bauthor%5D=31292>
- [5] <http://okina.univ-angers.fr/publications?f%5Bauthor%5D=31293>
- [6] <http://okina.univ-angers.fr/publications?f%5Bauthor%5D=31294>
- [7] <http://okina.univ-angers.fr/publications?f%5Bauthor%5D=31295>
- [8] <http://okina.univ-angers.fr/publications?f%5Bauthor%5D=31296>
- [9] <http://okina.univ-angers.fr/dluquepaz/publications>
- [10] <http://okina.univ-angers.fr/publications?f%5Bauthor%5D=31298>
- [11] <http://okina.univ-angers.fr/publications?f%5Bauthor%5D=31299>
- [12] <http://okina.univ-angers.fr/publications?f%5Bauthor%5D=31300>
- [13] <http://okina.univ-angers.fr/publications?f%5Bauthor%5D=31301>
- [14] <http://okina.univ-angers.fr/publications?f%5Bauthor%5D=31302>
- [15] <http://okina.univ-angers.fr/publications?f%5Bauthor%5D=31303>
- [16] <http://okina.univ-angers.fr/publications?f%5Bauthor%5D=31304>
- [17] <http://okina.univ-angers.fr/publications/ua18249>
- [18] <http://dx.doi.org/10.1038/cmi.2016.42>
- [19] <https://www.nature.com/articles/cmi201642>
- [20] <http://www.ncbi.nlm.nih.gov/pubmed/27499044?dopt=Abstract>

Publié sur *Okina* (<http://okina.univ-angers.fr>)